Bionano Genomics, Inc. × BioDiscovery, Inc.
Bionano Genomics acquired BioDiscovery, a genomics software company, for up to $100 million in cash and equity. [46, 55] The primary asset was BioDiscovery's NxClinical software, a platform-agnostic solution for analyzing and visualizing genomic data from microarrays and next-generation sequencing (NGS). [46] Bionano plans to integrate its own optical genome mapping (OGM) data into the platform to create a more comprehensive genome analysis workflow. [48]
The asset
Acquisition of BioDiscovery, a software company specializing in genomics data analysis, interpretation, and reporting, primarily for its NxClinical software platform.
The record
- Seller status
- Going concern
- Sector
- Genomics software
- Modalities
- genomic data, software
- Jurisdiction
- US
- Personal data
- The acquired asset is a software platform for analyzing genomic data, not a dataset of PII itself. The platform is designed to handle various genomic data types like NGS and microarrays. [46]
What it means if you hold data
This deal represents the vertical integration of data generation (Bionano's OGM systems) and data interpretation (BioDiscovery's software). For labs and researchers, this promises a more unified workflow, potentially making complex, multi-source genomic data more accessible and easier to analyze.